

Becker, M.I., Baxter, J.D., Wessleman, C.W., Garrett, L., Lee, S.Y., Millard, D., and R. Haubrich. 2002. **Prevalence of HIV-1 Genotypic Resistance in Treatment-Naive Subjects Enrolled in an Observational Trial (GAIN Study).** Antiretroviral Therapy. Vol 7, S134

Chung, J., Mallari, R., Clark, N., Griswold, M.P., & D.G. Kahn. 1999. **Viral Load Measurements of HIV-1 Group M Non-B Subtypes by PCR.** Interscience Conference on Antimicrobial Agents and Chemotherapy.

Gorgi, A., Amitina, N., Curall, B., Wolfe, P., & A. Scarsella. February 28 – March 4, 2005. **Atazanavir Plasma Quantification Using Direct Injection Method Compared with Reversed-Phase Analytical Column Methodology by LC/MS/MS.** 56th Pittsburg Conference on Analytical Chemistry and Applied Spectroscopy. Orlando, FL

Gunawan, S., Gao, V.C.X., Griswold, M.P., & M. Van Gorder. March 2001. **Quantitative Determination of Antiretroviral Agent Efavirenz (Sustiva) in Human Serum/Plasma by Tandem LC-MS/MS.** Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy. New Orleans, LA

Gunawan, S, Lee, S.Y., Sandhu, M., Griswold, M.P., & D.G. Kahn. September 16 – 20, 2000. **HIV-1 Protease Inhibitor Drug Levels in Treatment Failure Patients.** 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada

Gunawan, S., M. Griswold, and D. Kahn. June 24-30, 2000. **LC-MS/MS Determination of Amprenavir (Agenerase) in Serum/Plasma of HIV-1 Infected Patients Receiving Combination Antiretroviral Therapy.** 24th International Symposium on High Performance Liquid Phase Separations and Related Techniques (HPLC 2000). Seattle, WA

Gunawan, S., M. Griswold, and D. Kahn. June 11-15, 2000. **Quantitative Determination of HIV-1 Inhibitors and its Metabolite in Patients Serum/Plasma by Tandem LC-MS/MS.** The 48th ASMS Conference on Mass Spectrometry and Allied Topics. Long Beach, CA.

Gunawan, S., M. Griswold, and D. Kahn. March 14-17. 2000. **Determination of HIV-1 Protease Inhibitors Amprenavir, Indinavir, Nelfinavir, Ritonavir, and Saquinavir in Human Serum/Plasma by Tandem Liquid Chromatography – Mass Spectrometry (LC-MS/MS).** 12th National HIV/AIDS Update Conference. San Francisco, CA.

Gunawan, S., M. Griswold, and M. Van Gorder. May, 2001. **LC-MS/MS Determination of Protease Inhibitor Lopinavir (Kaletra) in Plasma of HIV-1 Infected Patients.** 49th American Society for Mass Spectrometry Conference. Chicago, IL

Gunawan, S., B. Currall, T. Urmanita, and A.J. Scarsella. November 9-14, 2002. **Treatment Drug Level Monitoring of Antiretroviral Agents in Patients with AIDS.** American Association of Pharmaceutical Scientists Annual Conference. Toronto, Canada.

Gunawan, S., B. Currall, and A.J. Scarsella. July 19-24, 2003. **Monitoring of Total and Free (Unbound) Amprenavir Plasma Levels in HIV-1 Infected Patients.** 54th American Association for Clinical Chemistry Annual Meeting., Philadelphia, Pennsylvania.

Lee, S.Y. & Griswold, M.P. September 22-25, 2001. **Prevalence of PR/RT Mutations in Patients with Low-Level Treatment Failure.** 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL.

Lee, S.Y., Ding, N., Amitina, N., Wolfe, P., & A. Scarsella. November 10-13, 2004. **Triple-Probe Multiplex Real-Time PCR of HIV Proviral DNA.** 10th Annual Meeting of the Association for Molecular Pathology. Los Angeles, CA

Lee, S.Y., Amitina, N., Wolfe, P.R., Bowers, D.H. & A.J.Scarsella. October 30-November 2, 2004. **Molecular Diagnostics of Early HIV Infection in a High Risk Cohort.** 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.

Lee, S.Y., M. Sandhu, M.P. Griswold, and M. Van Gorder. February 4-8, 2001. **Validation of the Ultrasensitive HIV-1 Genotype Assay.** 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA

Lee, S.Y., M. Sandhu, F. Espin, M. Griswold and D. Kahn. May 21-25, 2000. **Alternate Approach to Identify HIV-1 RT-69 Insertion.** 100th General Meeting ASM, Los Angeles, CA.

Lee, S. Y., F. Espin, M. Sandhu, L. Shaker-Irwin, M. Griswold, and D. Kahn. February 25, 2000. **HIV-1 genotyping of Specimens with viral load <1,000 copies/mL.** 17th Annual AIDS Investigator's Meeting and 3rd Annual Conference of AIDS Research in California.

Lee, S. Y., F. Espin, J. Turner, M. Griswold, and D. Kahn. September 26-29, 1999. **Genotyping of HIV-1 Drug-Resistance: Comparison between in-house Procedure and Visible Genetics TruGene™ HIV-1 Assay.** 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Francisco, CA.

Lee, S.Y., M. Griswold, L. Shaker-Irwin, W. Hardy, A.J. Scarsella, E. Rogolsky, and R. Stryker. April 29 – May 2, 2001.**Reproducibility, Precision, and Turn-Around-Times of Results Generated by Laboratory-Developed “Home-**

Brew” Genotypic HIV-1 Drug Resistance Assays Vary Dramatically When Compared to Results Generated by a Kit-Based Genotyping Assay. 17th Annual Clinical Virology Symposium and Annual Meeting Pan American Society for Clinical Virology, Clearwater Beach, FL.

Luber, A.D., S. Gunawan, S.Y. Lee, M. Gonzalez, P. Chaturvedi, and A. Scarsella. March 30, 2000. **Serum Drug Levels of Amprenavir Display Limited Inter- and Intra-Patient Variability.** 1st International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam.

Luber, A.D., Gunawan, S., Lee, S.Y., Wolfe, P.R., Gonzalez, M., Aquino, G., Chaturvedi, P., & Scarsella, A. October 2000. **Serum and Plasma Drug Levels of Amprenavir Display Limited Inter- and Intra-Patient Variability.** 5th International Congress on Drug Therapy in HIV Infection. Glasgow, U.K.

Luber, A.D., Stryker, R., Burdick, J., Berry, N.M., Naderer, O., & Scarsella, A. October 2000. **Efficacy of Amprenavir (APV) 600 mg Plus Low-Dose Ritonavir (RTV) in Clinical Practice.** 5th International Congress on Drug Therapy in HIV Infection. Glasgow, U.K.

